论文部分内容阅读
目的:观察光动力疗法(PDT)联合玻璃体腔内注射抗VEGF药物(bevacizumab)治疗中心性渗出性脉络膜视网膜病变(CEC)的临床疗效和安全性。方法:经Amsler表、眼底检查、荧光素眼底血管造影(FFA)、吲哚青绿血管造影(ICGA)及光相干断层扫描(OCT)检查确诊为CEC患者24例24只眼,年龄15～54岁,平均年龄32.42岁。最佳矫正视力在0.01～0.5。PDT治疗,1周后在表面麻醉下玻璃体腔内注射bevacizumab1.25mg(0.0
Objective: To observe the clinical efficacy and safety of photodynamic therapy (PDT) and intravitreal injection of anti-VEGF drugs (bevacizumab) in the treatment of central exudative chorioretinopathy (CEC). Methods: 24 cases (24 eyes) of CEC were diagnosed by Amsler chart, fundus examination, fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA) and optical coherence tomography (OCT) , The average age of 32.42 years old. The best corrected visual acuity is 0.01 ~ 0.5. PDT treatment, 1 week after intravitreal injection of bevacizumab 1.25 mg (0.0